Expanding Access. Advancing Discovery.

Many insurance companies recognize the importance of exome sequencing for patients with unexplained epilepsy, and their coverage policies reflect that understanding. Our Epilepsy Partnership Program provides even greater access to exome testing for eligible patients.

Through our Autism Partnership Program, SHANK3 Genetic Testing, eligible patients who meet eight clinical criteria can receive guideline-backed exome testing with financial support.

Through our partnership with Chiesi Global Rare Diseases, eligible patients with suspected Alpha-Mannosidosis can receive no-cost genetic testing to help confirm diagnosis and guide appropriate clinical care.

Through our partnership with Chiesi Global Rare Diseases, eligible patients with suspected Fabry disease can receive no-cost genetic testing to support timely diagnosis and guide appropriate clinical care.